Drs Banu Arun and Hope S. Rugo discuss immunotherapy, immunotoxicity, and comorbidities among diverse patient populations in advanced and metastatic breast cancer.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982649). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

The Emerging CDK4/6 Inhibitor for Breast Cancer Treatment https://pubmed.ncbi.nlm.nih.gov/35251463/

Endocrine Therapy Combined With Targeted Therapy in Hormone Receptor-positive Metastatic Breast Cancer https://pubmed.ncbi.nlm.nih.gov/32852380/

Introduction to Antibody-Drug Conjugates https://pubmed.ncbi.nlm.nih.gov/34842621/

Trastuzumab Deruxtecan for Breast Cancer https://pubmed.ncbi.nlm.nih.gov/35704495/

Triple Negative Breast Cancer: A Thorough Review of Biomarkers https://pubmed.ncbi.nlm.nih.gov/31927455/

Immunotherapy in Breast Cancer: An Overview of Current Strategies and Perspectives https://pubmed.ncbi.nlm.nih.gov/36781869/

Post-neoadjuvant Treatment Strategies in Breast Cancer https://pubmed.ncbi.nlm.nih.gov/35267554/

PARP and PARG Inhibitors in Cancer Treatment https://pubmed.ncbi.nlm.nih.gov/32029455/

PD-1/PD-L1 Pathway: Current Researches in Cancer https://pubmed.ncbi.nlm.nih.gov/32266087/

Checkpoint Blockade in the Treatment of Breast Cancer: Current Status and Future Directions https://pubmed.ncbi.nlm.nih.gov/29808015/

Neoantigens: Promising Targets for Cancer Therapy https://pubmed.ncbi.nlm.nih.gov/36604431/

Atezolizumab and Nab-paclitaxel in Advanced Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/30345906/

Nab-paclitaxel Dose and Schedule in Breast Cancer https://www.medscape.com/viewarticle/849295

VENTANA PD-L1 (SP142) Assay https://www.accessdata.fda.gov/cdrh_docs/pdf16/p160002c.pdf

Primary Results From IMpassion131, a Double-blind, Placebo-controlled, Randomised Phase III Trial of First-line Paclitaxel With or Without Atezolizumab for Unresectable Locally Advanced/Metastatic Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34219000/

Pembrolizumab Plus Chemotherapy in Advanced Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/35857659/

Gemcitabine and Carboplatin for Pretreated Metastatic Breast Cancer: The Predictive Value of Immunohistochemically Defined Subtypes https://pubmed.ncbi.nlm.nih.gov/22350024/

PD-L1 IHC 22C3 PharmDx https://www.accessdata.fda.gov/cdrh_docs/pdf15/p150013c.pdf

Pembrolizumab for Early Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/32101663/

18th St. Gallen International Breast Cancer Conference 2023 https://www.oncoconferences.ch/events/sgbcc-2023/

Prognostic and Predictive Value of Immune-related Gene Expression Signatures vs Tumor-infiltrating Lymphocytes in Early-stage ERBB2/HER2-positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials https://pubmed.ncbi.nlm.nih.gov/36602784/

Molecular Subtypes and Imaging Phenotypes of Breast Cancer https://pubmed.ncbi.nlm.nih.gov/27599892/

I-SPY 2: A Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-risk Breast Cancer https://pubmed.ncbi.nlm.nih.gov/33312344/

Luminal B Breast Cancer: Patterns of Recurrence and Clinical Outcome https://pubmed.ncbi.nlm.nih.gov/27542253/

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) https://clinicaltrials.gov/ct2/show/NCT04895358

Utility of the CPS + EG Scoring System in Triple-negative Breast Cancer Treated With Neoadjuvant Chemotherapy https://pubmed.ncbi.nlm.nih.gov/34186505/